Showing results (61-70 of 410) with videos related to
Sort By:
Pageof 41
Cancer|September 5, 2020
Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitisMichael Li, Jordan S Sack, Osama E Rahma, et al.STAR Protocols|May 10, 2025
Protocol for in-plate staining of clinical peripheral blood mononuclear cell samples for high-throughput analysis via spectral flow cytometryIsabella Marciello, Sonya Feng, Ilana Gomez Diaz, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 20, 2017
Development of Bell's Palsy After Treatment With Ipilimumab and Nivolumab for Metastatic Melanoma: A Case ReportJulia M Zecchini, Sara Kim, Kendra Yum, et al.The Journal of Community and Supportive Oncology|February 11, 2016
Impact of inpatient radiation on length of stay and health care costsSofya Pintova, Randall F Holcombe, Seth Blacksburg, et al.Endocrine Reviews|September 6, 2018
Endocrine Toxicity of Cancer Immunotherapy Targeting Immune CheckpointsLee-Shing Chang, Romualdo Barroso-Sousa, Sara M Tolaney, et al.Cancer|January 10, 2018
Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical managementRomualdo Barroso-Sousa, Patrick A Ott, F Stephen Hodi, et al.STAR Protocols|October 28, 2020
High-Throughput Mass Cytometry Staining for Immunophenotyping Clinical SamplesEmily M Thrash, Katja Kleinsteuber, Emma S Hathaway, et al.Melanoma Research|February 21, 2012
c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potentialXinqi Wu, Jun Zhou, Andrew M Rogers, et al.Expert Review of Anticancer Therapy|November 13, 2015
Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapyKevin J Harrington, Igor Puzanov, J Randolph Hecht, et al.Journal of Neuro-Oncology|July 13, 2016
Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challengeDaniel N Cagney, Brian M Alexander, F Stephen Hodi, et al.Pageof 41